title: [A case of advanced sigmoid colon cancer performed resection of liver metastases after long-term control by S-1 and CPT-11 combination chemotherapy].
abstract: A 60-year-old man diagnosed as advanced sigmoid colon cancer was performed sigmoidectomy and D3 lymph node dissection. Intra-operative findings were SE, P0H1N4M (-), and Stage IV. One month after the operation, we started a combination chemotherapy using S-1 plus CPT-11 as one course for five weeks. S-1 (120 mg/body/day) was orally administered continuously for 3 weeks, and CPT-11 (80 mg/m2) was done intravenously on days 1 and 15. A Follow-up abdominal CT scan revealed a drastic reduction of liver metastasis and disappearance of para-aortic lymph node swelling (PR in). The combination chemotherapy was once finished after eight courses due to the patient's request. However, we started to administer the same regimen to him again six months later because of re-growth of liver metastasis. An additional six-course administration resulted in a reduction of liver metastasis by CT scan, and no other abnormal concentration besides two liver metastases by PET-CT examination was observed, and we performed a partial resection (two parts) of the liver and cholecystectomy 24 months after the first operation. The patient has been alive with disease free for five months since the second operation.
authors.affiliation: Dept. of Gastrointestinal Surgery, Kansai Rosai Hospital.
authors.forename: Shu
authors.initials: S
authors.lastname: Okamura
authors.forename: Ken
authors.initials: K
authors.lastname: Nakata
authors.forename: Rei
authors.initials: R
authors.lastname: Suzuki
authors.forename: Kumiko
authors.initials: K
authors.lastname: Uji
authors.forename: Atsuko
authors.initials: A
authors.lastname: Yoshida
authors.forename: Mio
authors.initials: M
authors.lastname: Yoshimura
authors.forename: Kaoru
authors.initials: K
authors.lastname: Okada
authors.forename: Shin
authors.initials: S
authors.lastname: Nakahira
authors.forename: Hirofumi
authors.initials: H
authors.lastname: Miki
authors.forename: Keishi
authors.initials: K
authors.lastname: Sugimoto
authors.forename: Shigeyuki
authors.initials: S
authors.lastname: Tamura
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002272:Carcinoembryonic Antigen / Q000097:blood; D004338:Drug Combinations; D006801:Humans; D000077146:Irinotecan; D008113:Liver Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010094:Oxonic Acid / Q000627:therapeutic use*; D049268:Positron-Emission Tomography; D012811:Sigmoid Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery; D005641:Tegafur / Q000627:therapeutic use*; D013997:Time Factors; D014057:Tomography, X-Ray Computed
chemical_list: D002272:Carcinoembryonic Antigen; D004338:Drug Combinations; C079198:S 1 (combination); D005641:Tegafur; D010094:Oxonic Acid; D000077146:Irinotecan; D002166:Camptothecin